Dihydromyricetin (DHM) for ALS
Also known as: DHM, Ampelopsin, Ampelopsis grossedentata extract
DHM's anti-inflammatory and GABAergic effects may reduce excitotoxicity and neuroinflammation in ALS.
Mechanism of Action
DHM modulates GABAergic inhibition to reduce glutamate excitotoxicity in motor neurons. It inhibits NLRP3 inflammasome activation in microglia and activates AMPK for metabolic neuroprotection.
General mechanism: Flavonoid. GABA-A positive modulator, AMPK/SIRT1 activator, NLRP3 inhibitor, PI3K/mTOR suppressor, hepatoprotective.
Current Evidence
Preclinical neuroprotection data. Anti-excitotoxic mechanism relevant to ALS glutamate hypothesis. No ALS trials.
Clinical Status: Preclinical. Available as supplement.
Safety Profile
Very safe. Well-tolerated. No significant side effects. Used traditionally in Chinese medicine.
Key Research Questions
- Can DHM's GABA modulation complement riluzole's anti-glutamate action?
- Does DHM reduce neuroinflammatory biomarkers in ALS?